Panic Disorder May Up Odds of Depression Rx Side Effects

Share this content:
Panic Disorder May Up Odds of Depression Rx Side Effects
Panic Disorder May Up Odds of Depression Rx Side Effects

MONDAY, Jan. 9, 2017 (HealthDay News) -- For patients with chronic depression, comorbid panic disorder is associated with increased likelihood of side effects during treatment, according to a study published online Jan. 3 in the Journal of Clinical Psychiatry.

Stewart A. Shankman, Ph.D., from the University of Illinois at Chicago, and colleagues examined the specificity of side effects among 808 chronically depressed individuals receiving antidepressants according to a predetermined algorithm for 12 weeks. Side effects (specific side effects and indicators of side effect burden) were assessed every two weeks.

The researchers found that lifetime diagnosis of panic disorder at baseline correlated with increased odds of gastrointestinal, cardiac, neurological, and genitourinary side effects during treatment (odds ratios, 1.6, 1.8, 2.6, and 3.0, respectively). For patients with versus those without panic disorder, increases in side effect frequency, intensity, and impairment over time were more strongly correlated with increases in depressive symptoms. There was no correlation for social phobia or generalized anxiety disorder with these effects.

"Potentially due to heightened interoceptive awareness of changes in their body, chronically depressed individuals with panic disorder may be at greater risk than those without panic disorder for antidepressant side effects and to experience a worsening of depressive symptoms as a result of these side effects over time," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »